10x Genomics, Inc. – NASDAQ:TXG
Founder-led company
10x Genomics stock price today
$13.438
-1.15
-7.89%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 16 hours
10x Genomics stock price monthly change
-16.58%
month
10x Genomics stock price quarterly change
-16.58%
quarter
10x Genomics stock price yearly change
-74.46%
year
10x Genomics key metrics
Market Cap | 1.70B |
Enterprise value | 5.90B |
P/E | -37 |
EV/Sales | 11.43 |
EV/EBITDA | -43.65 |
Price/Sales | 11.67 |
Price/Book | 7.48 |
PEG ratio | 0.24 |
EPS | -2.23 |
Revenue | 625.44M |
EBITDA | -224.31M |
Income | -264.30M |
Revenue Q/Q | 5.00% |
Revenue Y/Y | 16.64% |
Profit margin | -32.15% |
Oper. margin | -32.52% |
Gross margin | 76.69% |
EBIT margin | -32.52% |
EBITDA margin | -35.86% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for free10x Genomics stock price history
10x Genomics stock forecast
10x Genomics financial statements
| Jun 2023 | 146.81M | -62.41M | -42.51% |
|---|---|---|---|
| Sep 2023 | 153.64M | -92.98M | -60.52% |
| Dec 2023 | 183.97M | -48.95M | -26.61% |
| Mar 2024 | 141.00M | -59.94M | -42.52% |
| Sep 2025 | 203.28M | -21.11M | -10.39% |
|---|---|---|---|
| Oct 2025 | 197.56M | -25.22M | -12.77% |
| Dec 2025 | 218.88M | -10.90M | -4.98% |
| Mar 2026 | 188.71M | 17.18M | 9.11% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 989638000 | 196.33M | 19.84% |
|---|---|---|---|
| Sep 2023 | 948540000 | 203.32M | 21.44% |
| Dec 2023 | 965143000 | 224.1M | 23.22% |
| Mar 2024 | 922913000 | 204.07M | 22.11% |
| Jun 2023 | -11.52M | -4.46M | 7.09M |
|---|---|---|---|
| Sep 2023 | -25.30M | 4.9M | 4.37M |
| Dec 2023 | 25.75M | 13.09M | 5.61M |
| Mar 2024 | -15.72M | 10.63M | 1.63M |
10x Genomics alternative data
| Aug 2023 | 1,243 |
|---|---|
| Sep 2023 | 1,243 |
| Oct 2023 | 1,243 |
| Nov 2023 | 1,243 |
| Dec 2023 | 1,243 |
| Jan 2024 | 1,243 |
| Feb 2024 | 1,243 |
| Mar 2024 | 1,259 |
| Apr 2024 | 1,259 |
| May 2024 | 1,259 |
| Jun 2024 | 1,259 |
| Jul 2024 | 1,259 |
10x Genomics other data
43.06%
-33.75%
of TXG is owned by hedge funds
171
-91
49.02M
-38.62M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 0 | 2000 |
| Jan 2024 | 0 | 4000 |
| Feb 2024 | 0 | 13299 |
| Mar 2024 | 0 | 4660 |
| May 2024 | 0 | 11900 |
| Aug 2024 | 0 | 14061 |
| Nov 2024 | 0 | 12500 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | SAXONOV SERGE director, officer.. | Class A Common Stock | 12,000 | $1.2 | $14,400 | ||
Option | SAXONOV SERGE director, officer.. | Stock Option (right to buy) | 12,000 | $1.2 | $14,400 | ||
Sale | SAXONOV SERGE director, officer.. | Class A Common Stock | 6,693 | $13.69 | $91,614 | ||
Sale | HINDSON BENJAMIN J. director, officer.. | Class A Common Stock | 5,807 | $13.69 | $79,486 | ||
Sale | SAXONOV SERGE director, officer.. | Class A Common Stock | 6,749 | $22.53 | $152,055 | ||
Sale | HINDSON BENJAMIN J. director, officer.. | Class A Common Stock | 4,351 | $22.53 | $98,028 | ||
Sale | MCANEAR JUSTIN J. other: Former Chi.. | Class A Common Stock | 2,961 | $22.53 | $66,711 | ||
Sale | MCANEAR JUSTIN J. officer: Chief Fi.. | Class A Common Stock | 2,936 | $24.3 | $71,357 | ||
Sale | SAXONOV SERGE director, officer.. | Class A Common Stock | 4,877 | $24.3 | $118,531 | ||
Sale | HINDSON BENJAMIN J. director, officer.. | Class A Common Stock | 4,087 | $24.3 | $99,330 |
| Patent |
|---|
Grant Filling date: 1 Sep 2020 Issue date: 13 Sep 2022 |
Grant Filling date: 9 Apr 2020 Issue date: 13 Sep 2022 |
Grant Filling date: 29 Dec 2021 Issue date: 6 Sep 2022 |
Application Filling date: 25 Feb 2022 Issue date: 1 Sep 2022 |
Application Filling date: 24 Feb 2022 Issue date: 1 Sep 2022 |
Application Filling date: 12 May 2022 Issue date: 25 Aug 2022 |
Application Filling date: 10 Jan 2022 Issue date: 25 Aug 2022 |
Grant Filling date: 20 Apr 2020 Issue date: 23 Aug 2022 |
Application Filling date: 1 Oct 2021 Issue date: 18 Aug 2022 |
Grant Utility: Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same Filling date: 17 Dec 2019 Issue date: 16 Aug 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 30 Apr 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 15 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q1 2023 3 May 2023 | Q1 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Serge Saxonov Ph.D. (1977) Co-Founder, Chief Executive Officer & Director | $654,990 |
| Dr. Benjamin J. Hindson Ph.D. (1975) Co-Founder, Pres, Chief Scientific Officer & Director | $614,970 |
| Mr. Bradford J. Crutchfield (1963) Chief Commercial Officer | $350,000 |
Ms. Ruth De Backer (1977) Chief Bus. Officer | $337,810 |
| Mr. Justin J. McAnear (1976) Chief Financial Officer | $330,000 |
10x Genomics: Sticking To The Plan To Avoid The Falling The Knife
Lab Instrument Industry Update - New Commercial Entrants
10x Genomics: Still Waiting For Entry
10x Genomics: Unveiling The Investment Potential
10x Genomics: Recent Performance Amplifies My Bullish Conviction
10x Genomics: Growth Outweighing The Risks
A Deep Dive Into 10x Genomics, A Promising Portfolio
Singular Genomics: Betting On Expanding Genomics Systems Market
Bruker Corp.: My Top Ranked Holding In Laboratory Analytical Instruments
-
What's the price of 10x Genomics stock today?
One share of 10x Genomics stock can currently be purchased for approximately $13.44.
-
When is 10x Genomics's next earnings date?
Unfortunately, 10x Genomics's (TXG) next earnings date is currently unknown.
-
Does 10x Genomics pay dividends?
No, 10x Genomics does not pay dividends.
-
How much money does 10x Genomics make?
10x Genomics has a market capitalization of 1.70B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 19.81% to 618.73M US dollars.
-
What is 10x Genomics's stock symbol?
10x Genomics, Inc. is traded on the NASDAQ under the ticker symbol "TXG".
-
What is 10x Genomics's primary industry?
Company operates in the Healthcare sector and Medical - Healthcare Information Services industry.
-
How do i buy shares of 10x Genomics?
Shares of 10x Genomics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are 10x Genomics's key executives?
10x Genomics's management team includes the following people:
- Dr. Serge Saxonov Ph.D. Co-Founder, Chief Executive Officer & Director(age: 48, pay: $654,990)
- Dr. Benjamin J. Hindson Ph.D. Co-Founder, Pres, Chief Scientific Officer & Director(age: 50, pay: $614,970)
- Mr. Bradford J. Crutchfield Chief Commercial Officer(age: 62, pay: $350,000)
- Ms. Ruth De Backer Chief Bus. Officer(age: 48, pay: $337,810)
- Mr. Justin J. McAnear Chief Financial Officer(age: 49, pay: $330,000)
-
Is 10x Genomics founder-led company?
Yes, 10x Genomics is a company led by its founders Dr. Serge Saxonov Ph.D. and Dr. Benjamin J. Hindson Ph.D..
-
How many employees does 10x Genomics have?
As Jul 2024, 10x Genomics employs 1,259 workers.
-
When 10x Genomics went public?
10x Genomics, Inc. is publicly traded company for more then 6 years since IPO on 12 Sep 2019.
-
What is 10x Genomics's official website?
The official website for 10x Genomics is 10xgenomics.com.
-
Where are 10x Genomics's headquarters?
10x Genomics is headquartered at 6230 Stoneridge Mall Road, Pleasanton, CA.
-
How can i contact 10x Genomics?
10x Genomics's mailing address is 6230 Stoneridge Mall Road, Pleasanton, CA and company can be reached via phone at +92 54017300.
10x Genomics company profile:
10x Genomics, Inc.
10xgenomics.comExchange:
NASDAQ
Full time employees:
1,259
Industry:
Medical - Healthcare Information Services
Sector:
Healthcare
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
6230 Stoneridge Mall Road
Pleasanton, CA 94588-3260
Pleasanton, CA 94588-3260
CIK: 0001770787
ISIN: US88025U1097
CUSIP: 88025U109
